Search
HCW 2026: Switzerland based Oculis focuses today on neuro-ophthalmology, which has led them to a pivotal trial in optic neuritis and key mid-stage data coming this year in dry eye disease
CEO Riad Sherif describes the phase 2 data Oculis delivered in optic neuritis with privosegtor last year and he previews data the company will have soon for licaminlamab in dry eye. Coverage brought to you by
3 hours ago
London Healthcare Week: Oculis is aiming to redefine ophthalmology through methods like an eye drop technology that can reach the back of the eye and precision medicine like patient selection
CEO Riad Sherif introduces us to the company's programs in areas such a diabetic macular edema and dry eye. A phase 2 study in acute...
Nov 19, 2024
.png){kind=logo}